SCHEMBL11943535

SCHEMBL11943535

CSc1c(N2CCN(C)CC2)cnn(-c2ccc(F)cc2)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.53
LMNA P02545 4/20 0.53
POLB P06746 2/20 0.53
KMT2A Q03164 1/20 0.53
ALDH1A1 P00352 8/20 0.44
PPARG P37231 3/20 0.44
NCOA2 Q15596 3/20 0.44
NCOA1 Q15788 3/20 0.44
NPSR1 Q6W5P4 3/20 0.44
MAPK14 Q16539 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
RAB9A P51151 5/20 0.42
NPC1 O15118 4/20 0.42
TP53 P04637 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
MAPT P10636 4/20 0.40
DCTPP1 Q9H773 1/20 0.39
CA12 O43570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943538 0.82 ALDH1A1 (0.62) SMN1; SMN2LMNAPOLBKMT2AALDH1A1
SCHEMBL11943536 0.78 SMN1; SMN2 (0.50) SMN1; SMN2LMNAPOLBKMT2AALDH1A1
SCHEMBL13219453 0.72 ALDH1A1 (0.59) SMN1; SMN2LMNAPOLBKMT2AALDH1A1
SCHEMBL5224110 0.71 KMT2A (0.50) SMN1; SMN2LMNAPOLBKMT2AALDH1A1
SCHEMBL11946121 0.70 ALDH1A1 (0.51) SMN1; SMN2LMNAPOLBKMT2AALDH1A1
SCHEMBL13304482 0.70 SMN1; SMN2 (0.57) SMN1; SMN2LMNAPOLBKMT2AALDH1A1
SCHEMBL11943534 0.69 ALDH1A1 (0.73) SMN1; SMN2LMNAPOLBKMT2AALDH1A1
SCHEMBL11945591 0.68 SMN1; SMN2 (0.56) SMN1; SMN2LMNAPOLBKMT2AALDH1A1
SCHEMBL13135643 0.67 LMNA (0.49) SMN1; SMN2LMNAPOLBKMT2AALDH1A1
SCHEMBL11945511 0.67 SMN1; SMN2 (0.54) SMN1; SMN2LMNAPOLBKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA SMN1; SMN2 3911/4885LMNA 929/4885POLB 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.